Barinthus Biotherapeutics PLC
NASDAQ:BRNS
Barinthus Biotherapeutics PLC
NASDAQ:BRNS
Price:
0.6
USD
Market Closed
Market Cap:
$24.5m
Relative Value
The Relative Value of one
BRNS
stock under the Base Case scenario is
0.61
USD.
Compared to the current market price of 0.6 USD,
Barinthus Biotherapeutics PLC
is
Undervalued by 2%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
BRNS
Relative Value
Base Case
0.61
USD
Undervaluation 2%
Multiples Across Competitors
BRNS Competitors Multiples
Barinthus Biotherapeutics PLC Competitors
Barinthus Biotherapeutics PLC Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| UK |
|
Barinthus Biotherapeutics PLC
NASDAQ:BRNS
|
24.5m USD | 0 | -0.4 | 1.4 | 1.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
402.2B USD | 6.7 | 171.3 | 16.6 | 23.5 | |
| US |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
326.4B USD | 462 374.5 | -2 631.9 | -2 389.6 | -2 389.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
206.8B USD | 5.6 | 26.9 | 15.3 | 15.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
182.9B USD | 6.2 | 21.5 | 14.6 | 14.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
122.6B USD | 10.2 | 31.1 | 23.8 | 24.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83.3B USD | 5.8 | 18.5 | 14 | 15.9 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.2B EUR | 13.8 | 32.5 | 55.4 | 57 | |
| AU |
|
CSL Ltd
ASX:CSL
|
70.7B AUD | 3.2 | 16.6 | 11.4 | 14.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
